While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to ...

After striking a Most Favored Nation deal with the White House in January, Johnson & Johnson will now offer Xarelto at 68% ...

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics ...

While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s ...

Women and nonwhite racial/ethnic groups are still earning less in the life sciences. An industry consultant discusses the pay ...

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s ...

In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, ...